echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Development of tumor-infiltrating lymphocyte therapy to treat solid tumors Xinwei received $115 million in assistance

    Development of tumor-infiltrating lymphocyte therapy to treat solid tumors Xinwei received $115 million in assistance

    • Last Update: 2021-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 9, Obsidian Therapeutics announced the completion of a US$115 million Series B financing


    TIL is a tumor-infiltrating lymphocyte isolated from a patient's tumor tissue, which is expanded in vitro and then infused back into the patient's body


    cytoTIL15 is Obsidian's leading cytoTIL project and is currently in the preclinical development stage for the treatment of metastatic melanoma and other solid tumors


    ▲Obsidian's cytoTIL project pipeline (picture source: Obsidian official website)

    Reference materials:

    [1] Obsidian Therapeutics Announces Closing of $115 Million Series B Financing.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.